Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances

Ocugen (OCGN) detailed an R&D regulatory roadmap for three late-stage retinal programs, targeting biologics license applications (BLAs) next year for retinitis pigmentosa and Stargardt disease. A third BLA for geographic atrophy is targeted for 2028. The update is supportive for long-term pipeline visibility, but lacks near-term financial catalysts in the headline.

Analysis

Ocugen (OCGN) detailed an R&D regulatory roadmap for three late-stage retinal programs, targeting biologics license applications (BLAs) next year for retinitis pigmentosa and Stargardt disease. A third BLA for geographic atrophy is targeted for 2028. The update is supportive for long-term pipeline visibility, but lacks near-term financial catalysts in the headline.